Allogeneic Transplantation
Non-Cancerous Blood Disorder Trials
COMIRB: 23-0481
An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy without First-line Therapeutic Plasma Exchange in Adults with Immune-mediated Thrombotic Thrombocytopenic Purpura / EFC16521 –MAYARI
Principal Investigator: Ara Metjian
Eligibility: Ages 18-80; iTTP (initial or recurrent and a French TMA score of 1 or 2)
COMIRB: 23-1265
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Principal Investigator: Gemlyn George
Eligibility: Ages ≥ 18; Recent unfractionated heparin or low-molecular-weight heparin exposure
COMIRB: 21-3149
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension
Principal Investigator: Ara Metjian
Eligibility: Ages ≥ 18; Diagnosed with warm autoimmune hemolytic anemia (wAIHA) for at least 3 months; must be able to understand and voluntarily provide written informed consent
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.